As a major Ca 2+ pump in the sarcoplasmic reticulum of the cardiomyocyte, SERCA2a (sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase 2a) controls the relaxation and contraction of the cardiomyocyte.
It is meticulously regulated by adapting its expression levels and affinity for Ca 2+ ions to the physiological demand of the heart. Dysregulation of the SERCA2a activity entails poor cardiomyocyte contractility, resulting in heart failure. Conversely, improving cardiac SERCA2a activity, e.g. by boosting its expression level or by increasing its affinity for Ca 2+ , is a promising strategy to rescue contractile dysfunction of the failing heart.
The structures of the related SERCA1a Ca 2+ pump and the Na + /K + -ATPase of the plasma membrane exposed the pumping mechanism and conserved domain architecture of these ion pumps. However, how the Ca 2+ affinity of SERCA2a is regulated at the molecular level remained unclear. A structural and functional analysis of the closely related SERCA2b Ca 2+ pump, i.e. the housekeeping Ca 2+ pump found in the endoplasmic reticulum and the only SERCA isoform characterized by a high Ca 2+ affinity, aimed to fill this gap. We demonstrated the existence of a novel and highly conserved site on the SERCA2 pump mediating Ca 2+ affinity regulation by the unique C-terminus of SERCA2b (2b-tail). It differs from the earlier-described target site of the affinity regulator phospholamban. Targeting this novel site may provide a new approach to improve SERCA2a function in the failing heart. Strikingly, the intramembrane interaction site of the 2b-tail in SERCA2b shares sequence and structural homology with the binding site of the β-subunit on the α Na + /K + -ATPase. Thus P-type ATPases seem to have developed related mechanisms of regulation, and it is a future challenge for us to discover these general principles of P-type regulation.
Regulation of SERCA2a activity controls cardiac contractility
Muscle contraction is initiated by a transient release of Ca 2+ ions from the SR (sarcoplasmic reticulum) into the cytosol [1] . The Ca 2+ content of the SR will determine how much Ca 2+ can be released for contraction, which makes it an important determinant of contractile strength. In cardiac muscle, Ca 2+ uptake into the SR is almost exclusively catalysed by SERCA2a (sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase 2a), which couples the energy of ATP hydrolysis to the transport of two Ca 2+ ions across the SR membrane. SERCA2a not only determines the amount of Ca 2+ in the SR available to activate the next contraction, but also controls to a large extent the rate of cardiac relaxation. After a Ca transports approximately 50-90 % of the Ca 2+ back into the SR [1] .
The expression level of SERCA2a significantly affects cardiac SR Ca 2+ uptake and overall cardiac contractile properties [2] . But it is the acute regulation of SERCA2a activity that allows a fast beat-to-beat control of the contractile properties of the heart. It is therefore not surprising that the activity of the Ca 2+ pump is under strict control and is constantly adjusted to meet the physiological demand of the heart [3, 4] . SERCA2 is encoded by the ATP2A2 gene. First, the level of expression and alternative splicing are controlled at the transcript level [4] . In general, there is a strong correlation between the SERCA2a mRNA and protein levels and the number of transcripts will determine the protein level and overall capacity of Ca 2+ transport [2] . Both the promoter activity [5] and mRNA stability [6] are tightly regulated in the heart. However, adjusting the expression level to the physiological demand remains a very slow process in view of the slow turnover of the SERCA2a protein (an estimated 2-3 day half-life time) [7] . Besides its expression level, alternative processing (splicing and polyadenylation) of the ATP2A2 transcript is also strictly controlled. Early in the developing heart, the ATP2A2 transcript is alternatively processed by a so far poorly understood, but highly conserved, mechanism [4, 8] . This results in the expression of the more specialized and muscle-specific SERCA2a variant instead of the housekeeping SERCA2b variant that is present in all cells ( Figure 1 ). In SERCA2a, the 49-amino-acidlong C-terminus of SERCA2b (2b-tail) is replaced by a much shorter, four-amino-acid, tail. Without this 2b-tail, SERCA2a displays a 2-fold higher maximal turnover rate, but a lower apparent Ca 2+ affinity compared with SERCA2b [9] . The physiological importance of this cardiac isoform switch was investigated in-depth in a genetically modified mouse model in which the alternative ATP2A2 processing towards the SERCA2a isoform was prevented. This resulted in a replacement of SERCA2a by SERCA2b in the heart that was accompanied by a somewhat unexpected downregulation of total cardiac SERCA2 levels by approximately 40 % [10] . Although these mice developed mild concentric left ventricular hypertrophy, the SERCA2b Ca 2+ pump is able to preserve normal contractile function despite its lower expression levels [10] [11] [12] . This questioned why the heart expresses the specialized SERCA2a isoform in the first place. Recent simulations of Ca 2+ signalling in a murine cardiomyocyte now suggest that, under resting conditions, i.e. at a low adrenergic tone, the SERCA2a pump performs less efficiently than the higher-Ca 2+ -affinity variant SERCA2b owing to a higher pumping activity of SERCA2b at low cytosolic Ca 2+ concentrations (50-200 nM) [13] . However, SERCA2a would represent a better compromise between performance in resting conditions and during β-adrenergic stress when the cytosolic Ca 2+ load significantly increases. Indeed, Ca 2+ removal by the SERCA2a pump is more efficient at high cytosolic Ca 2+ load due to its higher maximal pumping rate and lower apparent affinity for Ca 2+ [13] . Experimental evidence supports this hypothesis, since SR Ca 2+ uptake in the SERCA2b mice is impaired at high Ca 2+ loads and during β-adrenergic stimulation [11, 12] . Thus SERCA2a appears to be specifically adapted to work under a broader dynamic range of cytosolic Ca 2+ concentrations from rest to maximal adrenergic stimulation [13] .
A second, more rapid, mechanism of SR Ca 2+ uptake control is the dynamic regulation of the pump's apparent affinity for Ca 2+ ions [14] . Although the cardiac SERCA2a isoform already operates with a lower Ca 2+ affinity than the SERCA2b variant found in most other cells, SERCA2a's apparent Ca 2+ affinity can be reduced even further by the direct interaction with one or both of two related small TM (transmembrane) proteins, i.e. PLB (phospholamban) in the atria and ventricles and sarcolipin in the atria [15] (Figure 1 ). PLB and sarcolipin act as inhibitors of the SR Ca 2+ -ATPase, but this inhibition is relieved during β-adrenergic stress by phosphorylation of PLB on Ser 16 and Thr 17 [16] , or of sarcolipin presumably on Thr 5 [17] . This results in a very rapid and robust increase in SR Ca 2+ uptake, with a strong impact on cardiac relaxation and contraction, making PLB and, presumably, also sarcolipin important mediators of the cardiac stress response [15] . PLB and/or sarcolipin fit into a hydrophobic cleft found in the TM region of the Ca 2+ pump that is formed by TM helices 2, 4, 6 and 9 [18, 19] . By counteracting the closure of the hydrophobic cleft that normally follows the binding of Ca 2+ to the pump, this interaction forces the pump to dwell longer in its Ca 2+ free conformation (E2). Thus these inhibitors exert a kinetic effect on the pump's catalytic cycle that decreases the apparent affinity for cytosolic Ca 2+ [15] . Finally, an increasing number of other protein interactors (such as HAX-1, HRC or S100A1) and post-translational modifications (such as nitrosylation, phosphorylation or SUMOylation) have now been discovered, which alter the pump's stability and activity, further highlighting the central role of SERCA2a in cardiac function (reviewed in depth elsewhere [3, 4] ).
Abnormal SERCA2a activity in heart failure
Heart failure is the leading cause of hospitalization and death in the developed world and is defined as the inability of the heart to supply sufficient blood flow to meet the body's needs. The poor contractile properties of the failing cardiomyocytes are typically associated with abnormal Ca 2+ cycling such as a reduced Ca 2+ content in the SR [15, 20, 21] . In part, this is reflected by impaired SR Ca 2+ uptake because of a lower SERCA2a expression level. Together with unchanged PLB expression levels, the PLB/SERCA2a ratio increases in conditions of heart failure, leading to a lower apparent Ca 2+ affinity of the pump at rest. Moreover, the lower degree of PLB phosphorylation was also reported as a possible complicating factor contributing to the impaired cardiac contractility of the failing heart [4, 15, 21] .
The importance of a proper control of the Ca 2+ affinity is underscored further by the discovery of several PLB mutants triggering the onset of familial dilated cardiomyopathy. PLB mutations causing a chronic reduction in the apparent Ca 2+ affinity lead to depressed SR Ca 2+ uptake and heart failure [22] [23] [24] . Moreover, and quite unexpectedly, a higher apparent Ca 2+ affinity resulting from the absence of PLB also triggers heart failure in humans [25] , although not in mice [26] . In mice, cardiomyopathy is only observed upon a combined deletion of PLB and sarcolipin [27] or expression of the highCa 2+ -affinity variant SERCA2b [10, 12] . Both mouse models develop cardiac hypertrophy. These studies show that the apparent Ca 2+ affinity of SERCA2a in cardiac SR needs to be controlled within a tight window to ensure normal cardiac function and growth [4, 21] .
In the last decade, several strategies were explored in cellular and animal models to improve the contractile properties of the cardiomyocyte by increasing the activity of SERCA2a [20] . One promising approach in humans is to increase SERCA2a expression via adeno-associated viral gene transfer of SERCA2a under control of a cardiacspecific myosin heavy chain α promoter (in Phase II clinical trial, CUPID study) [28, 29] . The observation that, in the normal physiological setting, SERCA2a activity in the heart is dynamically adjusted to the physiological demand by modulating its affinity for Ca 2+ suggests that other interventions, aimed to increase SERCA2a's Ca 2+ affinity, represent another strategy to effectively improve the activity of the pump [15, 30] . The proof-of-concept was provided in several animal models in which the inhibition of the pump by PLB was diminished, e.g. by long-term cardiactargeted RNA interference of PLB [30] or by overexpression of pseudo-phosphorylated constitutively active PLB (PLB-S16E) [31] .
Structure-function relationship of the ubiquitous SERCA2b pump
Since controlling the apparent Ca 2+ affinity of the Ca 2+ pump is of paramount importance for cardiac function, we elaborate on the molecular mechanisms of Ca 2+ -affinity regulation. Already more than 10 years ago, the first high-resolution crystal structure of the fast-twitch skeletal-muscle isoform SERCA1a was published [32] . More recently, structures of other archetypal P-type ATPases were solved (Na + /K + -ATPase [33, 34] and H + -ATPase [35] ), indicating that the general architecture of the P-type ATPases is very well conserved and contains four typical domains: a transmembrane domain (M) containing the binding sites of the transported ions, and three clearly defined cytosolic domains [a nucleotide-binding (N), phosphorylation (P) and actuator (A) domain] (Figure 1 ).
So far, over 20 high-resolution crystal structures of SERCA1a have been published covering almost all conformations of the kinetic cycle, yielding detailed molecular insights into the Ca 2+ -pumping mechanism (reviewed in [36] [37] [38] ). ATP binding occurs on the N-domain, whereas the P-domain catalyses ATP hydrolysis. The P-domain contains a key aspartate residue, which is the acceptor of the γ -phosphate of ATP leading to autophosphorylation of the pump when Ca 2+ is bound (hence the name P-type ATPase). Later in the cycle, the phosphorylated aspartate residue becomes dephosphorylated by the A-domain via a conserved glutamate residue, which catalyses the event. The phosphorylated aspartate residue is temporarily protected against dephosphorylation, but, since the A-domain rotates in the pump cycle, the catalysing glutamate residue becomes properly positioned to catalyse the dephosphorylation. Importantly, the phosphorylation and dephosphorylation of the pump is tightly linked with the closure of the cytosolic or luminal gate respectively, restricting access to the Ca 2+ binding site. This coupling ensures that both gates are never open at the same time, i.e. first, the cytosolic gate closes and Top right: structural model of SERCA2b in the Ca 2+ -bound E1 conformation [39] . Luminal loop L7-L8 is indicated in light yellow, and is a crucial interaction site of the 2b-tail. Light orange, N-domain; blue, P-domain; green, A-domain; grey, M-domain. Left: detailed view of the interaction site of the extra TM segment TM11 (dark blue) on the region TM7 and TM10 of the SERCA pump. Bottom right panel: detailed view of the luminal interaction site of the 2b-tail. Dark blue residues close to luminal loops L1-L2 and L3-L4 correspond to the residues M 1039 FWS of the luminal 2b-tail. In red, the residues that are important for 2b-tail function; mutating these residues reduces the apparent affinity of SERCA2b, but not that of SERCA2a.
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2+ ions are excluded before opening of the luminal gate can occur. This sequential opening is crucial to generate a 10 000-fold Ca 2+ gradient across the SR membrane [36] [37] [38] . Less structural information is available for other SERCA isoforms. The SERCA2 proteins, with the variants SERCA2a and SERCA2b, share over 80 % sequence identity with SERCA1a, which points to a common Ca 2+ -pumping mechanism [39] . But the SERCA2b isoform differs from SERCA1a or SERCA2a by three related structural and functional features: SERCA2b has an extended 2b-tail and it presents a 2-fold higher affinity for cytosolic Ca 2+ ions and only half the maximal turnover rate of the two other isoforms. The 2b-tail comprises an additional TM segment (TM11), so that SERCA2b is the only known Ca 2+ pump with 11 TM helices. The 2b-tail ends with a small luminal extension comprising 12 residues S 1031 TDTNFSDMFWS 1042 [9, [39] [40] [41] . Functional measurements on SERCA2b mutants (e.g. alanine substitutions and partial truncations of the 2b-tail) revealed that both TM11 and the luminal extension contribute to the functional effect of the 2b-tail [39] (Figure 2) . First, mutations of any of the four C-terminal residues M 1039 FWS of the luminal extension to alanine affect the Ca 2+ affinity of SERCA2b. Secondly, the functional effect of the 2b-tail is partially preserved when 11 residues of the luminal extension are removed (T1032*), indicating that not only MFWS, but also a second region upstream of the luminal extension is also important (presumably TM11) [39] . In contrast, when all 12 residues of the luminal extension are truncated (S1031* mutation) the effect of the 2b-tail is completely abolished [39, 40] . Since the S1031A substitution has no functional effect, we hypothesize that TM11 is a second functional region that loses its function or membrane insertion when it is truncated at Ser 1031 , i.e. too close to the membrane [39] . When the 2b-tail is fused to the SERCA1a isoform (forming a SERCA1a2b chimaera), it partially increased the apparent Ca 2+ affinity of SERCA1a [39] . Further experiments pointed out that TM11, but not the luminal extension, is responsible for this effect, showing that the site where TM11 interacts with more upstream elements of the pump is conserved between SERCA1a and SERCA2. On the other hand, the luminal binding site for interaction with the luminal extension is not well conserved between both isoforms. The binding site for the luminal extension can only be established in SERCA1a2b provided that the luminal loop of L7-L8 of SERCA2b is inserted to replace the corresponding SERCA1a loop. Indeed, this substitution leads to a gainof-function of the 2b-tail in the SERCA1a2b chimaera, providing strong evidence that L7-L8 is an important interaction site for the luminal extension. We subsequently found two substitutions in L7-L8 of SERCA1a (L873M and K876T) that are responsible for the inability of the SERCA1a L7-L8 to interact with the luminal extension of the 2b-tail [39] (Figure 2) .
Apparently, TM11 does not disturb the interactions or movements of other TM helices that are required for normal pump function. Therefore the interaction of TM11 probably takes place on a conserved site that is exposed to the lipid environment in the TM domain of the pump. Mutations of exposed and conserved residues were tested in several TM helices, but only alanine substitutions of residues in TM7 and TM10 led to a reduced Ca 2+ affinity [39] (Figure 2 ). On the basis of the published SERCA1a crystal structures [32] and our own solved NMR structure of TM11 [39] , which is a short α-helix, a structural model for SERCA2b was proposed that is in agreement with the mutagenesis results (Figures 1  and 2 ). According to that model, TM11 interacts with a region formed by TM7 and TM10 of the pump, opening at its luminal side a groove between loops L5-L6 and L7-L8. This groove is important for the descent of the luminal extension towards a luminal pocket formed by all five luminal loops where the binding of residues M 1039 FWS takes place. The model provides an elegant explanation for the crucial effect of Leu 873 and Lys 876 on L7-L8 of SERCA2b, which are also found in this groove close to the luminal extension [39] .
According to some early reports, the chaperones calreticulin and calnexin would interact at the luminal side of SERCA2b with the residues N 1035 FS of the luminal extension of the 2b-tail [42, 43] . It was stated that the interaction with calreticulin or calnexin is required to render the specific enzymatic properties of SERCA2b. Since no N-glycosylation was observed on Asn 1035 , it was suggested that this interaction occurs in a glycosylation-independent manner [43] . Although we cannot rule out that calreticulin or calnexin interacts with the 2b-tail, our results question whether this interaction is crucial to render the high Ca 2+ affinity of SERCA2b. Indeed, we show that alanine mutants of the N 1035 FS region retain normal Ca 2+ -dependent ATPase activity when overexpressed in COS cells [39] . Moreover, according to the SERCA2b molecular model, the 2b-tail is buried in luminal loops of the pump, making its interaction with other proteins less likely [39] .
The mechanism by which the 2b-tail would increase the Ca 2+ affinity of the pump via an intramolecular interaction was explored further. We demonstrated that the luminal extension of the 2b-tail stabilizes the pump in the Ca 2+ -bound E1 conformation with high-affinity binding sites facing the cytosol. This fits with the proposed binding site of the C-terminal tetrapeptide of the luminal extension, which is situated in a luminal pocket formed by the five luminal loops of the pump. Mathematical modelling confirmed that holding the enzyme longer in the E1 conformation could explain the increased apparent affinity for Ca 2+ [39] . Moreover, structures of the SERCA1a pump in different conformations predict extensive rearrangements of the proposed luminal docking site of the luminal extension. Thus the binding of the luminal extension would slow down these rearrangements, which is in agreement with the experimentally observed slower E1-P-E2-P and E2-P-E2 transitions [39, 41] .
How the short TM11 α-helix alters the enzymatic properties of the pump needs further exploration, since TM11 binds at a remote and relatively immobile part of the TM region far from the catalytically important regions [39] . One striking observation is, however, the resemblance between the binding site of TM11 on the SERCA pump and the TM region of the β-subunit on the α-subunit of Na + /K + -ATPase, which is a known regulator of the apparent K + affinity of this pump [33, 34, 44] . Note that TM11 and the β-subunit independently originated in evolution, but apparently evolved to occupy existing hotspots for regulation on the related P-type ATPases SERCA2b and Na + /K + -ATPase [39] . Confirming this common mode of action would point to an exciting example of convergent evolution in the P-type ATPases. The same holds true for PLB and phospholemman (a member of the FXYD family also known as the γ -subunit of the Na + /K + -ATPase), which, although they originated independently in evolution, also occupy approximately the same binding site close to TM9 with similar modes of action and regulation [33, 34] . Thus P-type ATPases not only share a general architecture and domain organization, but also seem to have developed related mechanisms of regulation. It is a future challenge for us to discover these general principles of P-type regulation.
Purification of the ubiquitous SERCA2b pump
Another future goal is to verify the structural model by solving the atomic resolution structure of the SERCA2b pump. Although now readily feasible for SERCA1a, the much lower endogenous tissue expression has so far hampered purification efforts with SERCA2b [45] . We have developed a new affinity-purification strategy based on thapsigargin, a specific and highly potent inhibitor of SERCA (in the sub-nanomolar range) [46, 47] . Thapsigargin binds in a hydrophobic funnel-like cavity of the Ca 2+ pump formed by TM helices 3, 5 and 7 and inhibits the pump by preventing the movement of these helices relative to each other [47, 48] . A thapsigargin analogue was synthesized by S.B. Christensen (Copenhagen, Denmark) to allow coupling of the inhibitor to a Sepharose matrix for affinity chromatography of recombinantly expressed SERCA2b pump [45] . A second affinity-purification step, based on ATP analogues (reactive dyes) coupled to a carrier, was subsequently applied for further purification, concentration and detergent exchange. Without the necessity of adding tags that might interfere with pump function and structure, these affinity chromatography techniques allow the selective purification of correctly folded and functionally active SERCA2b. Note that amino acids forming the thapsigargin-binding pocket in SERCA1a are partially conserved in SPCA1 (secretory pathway Ca 2+ -ATPase 1) [45] . SPCA1 therefore also shows some sensitivity towards thapsigargin, but in a thapsigargin concentration range at least 1000-fold higher (micromolar concentration) than SERCA [38] . Interestingly, the successive thapsigargin and reactive dye purification could also be successfully employed to purify SPCA1 from the yeast overexpression system. The selective purification of SERCA and SPCA isoforms will enable future crystallization attempts of these housekeeping Ca 2+ pumps.
Conclusions
The diminished cardiac contractility in heart failure is partially explained by a reduced activity of the cardiac SERCA2a pump. Improving the expression or function of the Ca 2+ pump are potential strategies to improve cardiac contractility. One possible strategy is to increase the affinity of the pump for Ca 2+ ions. We have studied the molecular mechanism of the unique C-terminus of the ubiquitous SERCA2b isoform to obtain insights into the mechanisms of affinity regulation. We have developed a structural model of SERCA2b that explains extensive mutagenesis results and the mode of action of the 2b-tail. Finally, we have described the use of thapsigargin, a selective and potent SERCA inhibitor, to purify SERCA2b for subsequent structural studies.
Interestingly, the predicted docking site in SERCA2 for the TM11 region of the 2b-tail strikingly resembles the corresponding interaction site for the β-subunit on the α-subunit of the Na + /K + -ATPase, but it is distinct from the PLB site, which is situated at the opposite side of SERCA (Figure 1 ). We therefore hypothesize that targeting the 2b-tail interaction site may represent a novel approach to improve the activity of SERCA2a in heart failure, independently of PLB.
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